Quest Partners LLC purchased a new stake in shares of Enfusion, Inc. (NYSE:ENFN – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 32,482 shares of the company’s stock, valued at approximately $308,000.
A number of other hedge funds also recently made changes to their positions in the business. Gladius Capital Management LP raised its holdings in shares of Enfusion by 160.5% during the third quarter. Gladius Capital Management LP now owns 69,694 shares of the company’s stock valued at $661,000 after buying an additional 42,939 shares during the last quarter. Royce & Associates LP raised its holdings in shares of Enfusion by 35.4% during the third quarter. Royce & Associates LP now owns 99,715 shares of the company’s stock valued at $946,000 after buying an additional 26,045 shares during the last quarter. Impax Asset Management Group plc raised its holdings in shares of Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after buying an additional 136,948 shares during the last quarter. Versor Investments LP bought a new stake in shares of Enfusion during the third quarter valued at approximately $501,000. Finally, Belvedere Trading LLC bought a new stake in shares of Enfusion during the third quarter valued at approximately $114,000. Institutional investors own 81.05% of the company’s stock.
Enfusion Trading Down 2.7 %
ENFN opened at $10.08 on Tuesday. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $10.45. The stock has a market cap of $1.30 billion, a PE ratio of 259.06, a price-to-earnings-growth ratio of 3.87 and a beta of 0.93. The business’s 50 day moving average is $9.18 and its 200-day moving average is $8.86.
Enfusion Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Read More
- Five stocks we like better than Enfusion
- What is Short Interest? How to Use It
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- 3 Healthcare Dividend Stocks to Buy
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- How Technical Indicators Can Help You Find Oversold Stocks
- Discover the 3 Best Performing Stocks That Went Public in 2024
Want to see what other hedge funds are holding ENFN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN – Free Report).
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.